key: cord-0263552-s4lcz76i
authors: Cook, C.; Patel, N.; D'Silva, K.; Hsu, T. T.-Y.; DiIorio, M.; Prisco, L.; Martin, L.; Vanni, K. M. M.; Zaccardelli, A.; Todd, D. J.; Sparks, J.; Wallace, Z.
title: Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases
date: 2021-08-05
journal: nan
DOI: 10.1101/2021.08.04.21261618
sha: 83a1aa546981d2614940edc94e5ee7f69ca72d44
doc_id: 263552
cord_uid: s4lcz76i

Objective To describe the characteristics of COVID-19 vaccine breakthrough infections among systemic autoimmune rheumatic disease (SARD) patients. Methods We identified SARDs patients in a large healthcare system with COVID-19 vaccination at least 14 days prior to a positive SARS-CoV-2 molecular test. Details of the SARD diagnosis, vaccination status, and COVID-19 infection were extracted. Results Of 340 confirmed COVID-19 infections among SARDs patients between December 11th, 2020 (date of first COVID-19 vaccine approval in the US) and July 30th, 2021, we identified 16 breakthrough infections. Seven (44%) received the Pfizer-BioNtech vaccine, five (31%) received the Moderna vaccine, and four (25%) received the Janssen/Johnson & Johnson vaccine. The most common SARDs included rheumatoid arthritis (6, 38%), inflammatory myopathy (3, 19%), and systemic lupus erythematosus (3, 19%). Rituximab (5, 31%), glucocorticoids (4, 25%), and mycophenolate mofetil (4, 25%) were the most frequent treatments. Among the breakthrough infections, 15 (93%) were symptomatic, six (38%) were hospitalized, one (6%) required mechanical ventilation, and two (13%) died. Conclusions Symptomatic, including severe, breakthrough infections were observed in SARDs patients; many were on treatments associated with attenuated antibody responses to vaccination. Further studies are needed to determine the rate of breakthrough infection associated with SARD treatments and other features.

What is already known about this subject?

Breakthrough infections following COVID-19 vaccination are expected but some patients with systemic autoimmune rheumatic diseases (SARDs) may be at higher risk because of blunted antibody responses to vaccination associated with rheumatic disease treatments and other factors that remain poorly understood.

What does this study add?

We identify and describe 16 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021 We systematically identified breakthrough COVID-19 infections in a large healthcare system to characterize these cases and identify SARDs patients in whom clinical vaccine efficacy may be reduced.

Mass General Brigham (MGB) is a large multicenter health care system in the Boston, Massachusetts, USA area that includes tertiary care hospitals, community hospitals, and outpatient clinics. We utilized the MGB centralized data warehouse to identify patients who were ≥18 years of age and had positive polymerase chain reaction (PCR) testing for SARS-CoV-2 between January 30 th , 2020 and July 30 th , 2021. Patients with SARDs with a positive SARS-CoV-2 test were identified using diagnostic billing codes, as previously described (8) (9) (10) (11) (12) .

Additional cases with positive PCR or SARS-CoV-2 antigen test results were identified via physician referral from the MGB rheumatology clinics. Electronic health records of identified . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261618 doi: medRxiv preprint cases were manually reviewed to confirm the SARD diagnosis and gather details of COVID-19 infection, vaccination, and outcome. Patients with any history of COVID-19 vaccination prior to their COVID-19 molecular test were identified from this cohort. Breakthrough infections in fully vaccinated patients were considered to be those who had SARS-CoV-2 detected by either PCR or antigen testing at least 14 days after their final vaccine dose, as defined by the US Centers for Disease Control and Prevention (13). Partially vaccinated patients were considered to be those with a positive test between 7 and 14 days after their final dose. Final vaccination dose was considered either the first dose in a one-dose series (Janssen/J&J) or second dose in a two-dose vaccination series (Pfizer-BioNTech and Moderna). Descriptive statistics (mean, standard deviation, frequencies, proportions) were used.

Patients or the public were not involved in the design, conduct, reporting, or dissemination of this study.

Of 786 SARDs patients with COVID-19 infection identified within the MGB healthcare system, 340 occurred after the initial emergency use authorization for COVID-19 vaccination in the US (December 11 th , 2020). Of these, 40 (12%) received a COVID-19 vaccination prior to their earliest positive test, 16 (4.7%) of whom were classified as breakthrough infections ( Figure   1 ).

Among the 16 breakthrough infections, 12 (75%) were female, 11 (69%) were white, and the median age was 50 (IQR: 38, 64) years ( Table 1) . Twelve patients (75%) had at least one comorbidity. The most common SARDs included rheumatoid arthritis (6, 38%), inflammatory . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261618 doi: medRxiv preprint myositis (3, 19%) , and systemic lupus erythematosus (3, 19%) . Rituximab (5, 31%), glucocorticoids (5, 31%), mycophenolate mofetil or mycophenolic acid (4, 25%), and methotrexate (3, 19%) were the most frequent immunosuppressive medications recorded prior to first vaccine dose. In one case (6%), the patient was on no DMARD or glucocorticoid at the time of their COVID-19 vaccine. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. 

Among the 16 patients with breakthrough infections, 15 (93%) were symptomatic; the most frequent symptoms included fever (9, 56%), cough (7, 44%), and malaise (6, 38%) ( Table   1 ). One (6%) patient was asymptomatic; testing was performed for pre-procedure screening. Six (38%) patients were hospitalized during which four (25%) required supplemental oxygen and one (6%) required mechanical ventilation ( Table 2 ). The hospitalized patients had myositis (2, 13%), systemic lupus erythematosus (2, 13%), and rheumatoid arthritis (2, 13%). DMARDs used prior to infection among hospitalized patients included rituximab (4, 25%) and mycophenolate mofetil or mycophenolic acid (2, 13%).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261618 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261618 doi: medRxiv preprint Tables 1 and 2) .

A small portion of COVID-19 cases among SARDs patients in a large US healthcare system occurred among fully vaccinated patients. Reassuringly, the majority of these breakthrough infections were non-severe and managed as outpatients. However, some patients required hospitalization that ultimately culminated in death. The most commonly used SARDs treatments at the time of vaccination included those associated with blunted antibody responses to SARS-CoV-2 vaccination, including glucocorticoids, methotrexate, mycophenolate mofetil or mycophenolic acid, and rituximab (4-7). These results have immediate implications for SARDs patients.

In contrast to outcomes of breakthrough infections in the general population reported to the United States Centers for Disease Control and Prevention (n=10,262), we observed a larger proportion of patients who required hospitalization (40% vs. 10%) or died (13% vs. 2%) (13).

Outcomes in our cohort were also worse than those described in a study of fully-vaccinated skilled nursing home residents and staff (n=22), of whom 18% were hospitalized and 5% died . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261618 doi: medRxiv preprint (14) . While our small sample size limits the interpretation of these comparisons, the frequency with which use of DMARDs previously associated with blunted antibody responses were observed in our cohort is notable. Indeed, a study of patients hospitalized with breakthrough infections in Israel found that 40% of these patients were considered immunocompromised (15).

However, it is possible that we did not identify SARDs patients with asymptomatic or less severe breakthrough infections.

Collectively, these findings suggest that the blunted SARS-CoV-2 antibody response following COVID-19 vaccination in certain DMARD users may be associated with an increased risk of breakthrough infections that may be severe and even fatal. The protective role of SARS-CoV-2-specific T cell responses following vaccination among DMARD users is an area of active investigation, especially among B cell depleting agent users (4). However, our observation that rituximab was the most commonly used DMARD among patients with breakthrough infections and the DMARD used in both fatal cases, raises concerns regarding the ability to mount a T cell immune response against SARS-CoV-2 after B cell depletion. However, both patients also had severe pre-existing interstitial lung disease which likely also contributed to their poor clinical outcome. Some patients treated with B cell depleting agents may require alternative risk mitigation strategies, including passive immunity or booster vaccines, and may need to continue shielding practices (e.g., face masking, social distancing) as society continues to re-open, especially if they have a poor antibody response to vaccination. Perhaps reassuringly, some DMARDs commonly used to treat SARDs had either few (e.g., tumor necrosis factor inhibitors and interleukin-6 receptor inhibitors) or no (e.g., abatacept and Janus kinase inhibitors) (16) identified breakthrough infections in our case series.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261618 doi: medRxiv preprint Our study has certain strengths, including the systematic approach to case identification and SARD-specific details available from the EHR. Despite these strengths, our study has certain limitations. First, we could not estimate the rate of breakthrough infections among SARDs patients. Second, this was a retrospective study that identified patients who presented to care for SARS-CoV-2 PCR testing, so the proportion of asymptomatic breakthrough infections observed in our study may be an underestimate. Third, while the observed frequency of certain DMARD use (e.g., mycophenolate mofetil, rituximab) in our cohort suggests that the blunted antibody response associated with these DMARDs may put patients at risk for breakthrough infection, we did not have antibody testing available for all patients and cannot rule out the possibility that SARD manifestations (e.g., interstitial lung disease) commonly treated with these medications contributed to the severity of the presentation. Fourth, we were unable to determine whether DMARDs were held temporarily prior to or after vaccine doses as recommended by the American College of Rheumatology (17) since these changes were not consistently documented in the EHR.

In conclusion, a small minority of COVID-19 cases among SARDs patients in a large healthcare system occurred in fully vaccinated patients. However, a large portion of these cases required hospitalization and occurred among patients using DMARDs that have been previously associated with a blunted antibody response following vaccination. Additional studies are urgently needed to estimate the risk of breakthrough infections among SARDs patients and to evaluate the efficacy of booster vaccines and other strategies for DMARD users with poor immunologic response to COVID-19 vaccination.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261618 doi: medRxiv preprint

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Epub ahead of print

Incident systemic rheumatic disease following COVID-19

SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease

Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot

Laboratory trends, hyperinflammation, and clinical outcomes for patients with systemic rheumatic disease hospitalised for COVID-19: A comparative cohort study

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

COVID-19 Vaccine Breakthrough Infections Reported to CDC -United States

Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2